Which is true about antibiotic prescribing to reduce the risk of antimicrobial resistance development?
Most patients with asymptomatic bacteriuria should be treated with antibiotics to reduce risk of developing resistant E coli.
Uncomplicated acute cystitis should be treated for a minimum of 14 days of antibiotics.
Non-purulent uncomplicated cellulitis should be treated for a minimum of 5 days.
Community-acquired pneumonia should be treated with antibiotics for a minimum of 21 days before considering discontinuation.
Group A beta-hemolytic strep treated for less than 21 days is considered “partially treated” and risks transformation into resistant organisms.
You are correct. Using the shortest effective antibiotic duration reduces risks for side effects and antimicrobial resistance. In adult patients who have a timely clinical response, guidelines suggest the following durations for uncomplicated cases of these infections:
• Community-acquired pneumonia: 5 days
• Hospital-acquired pneumonia: 7 days
• Non-purulent cellulitis: 5 days
• Group A beta-hemolytic strep oral beta lactam treatment: 10 days
• UTI: duration varies based on drug used and whether patient has a catheter or a complicated UTI

Sources:
CDC Shortest Antibiotic Duration
CDC Adult Outpatient Treatment Recommendations
CDC Antibiotic Use Training Materials
Can you identify this pill?
cyclobenzaprine
ropinirole
alprazolam
lorazepam
You are correct. Alprazolam is a benzodiazepine indicated for anxiety and panic disorder in adults.

As a reminder, you can use the Pill ID feature to identify a pill based on its imprint code or physical characteristics, including shape, color, and scoring. Find Pill ID in the epocrates app or on epocrates Web.
(PubMed)—A 35-yo man w/ hx of Evans syndrome secondary to antiphospholipid syndrome presented w/ jaundice and SOB. Prior to presentation, his condition had been well controlled w/ cyclosporine 200 mg/day. Two months earlier he had been diagnosed w/ restrictive lung dz, which was treated w/ a steroid. To counteract steroid-related weight gain, the pt was prescribed orlistat, which he took at the same time as his cyclosporine. Other meds: warfarin. Labs—Hgb 9.3 g/dL, platelets 4 x109/L, INR 3.4, and positive direct Coombs tests—indicated a relapse of Evans syndrome.

What drug interaction could have led to the relapse?
cyclosporine and orlistat
orlistat and warfarin
warfarin and cyclosporine
orlistat and steroids
You are correct. This combination may decrease cyclosporine levels and efficacy, due to altered absorption. The combination should be avoided; if the 2 drugs must be used together, cyclosporine should be given 3h after orlistat.

Source article: Earnshaw I, Thachil J. Example of the drug interaction between ciclosporin and orlistat, resulting in relapse of Evan’s syndrome. BMJ Case Rep. 2016 Oct 28;2016. pii: bcr2016217246. doi: 10.1136/bcr-2016-217246.

More info is available, including the BMJ Case Rep abstract in PubMed.
Which of these are NOT recommended for treating/managing diabetic foot infections (DFIs)?
Use of adjunctive therapies (e.g., G-CSF, topical antiseptics, silver, honey, bacteriophages, topical antibiotics, hyperbaric oxygen) are recommended to promote healing.
In patients with DFI-associated osteomyelitis and amputation with positive bone margins, antibiotics are suggested for 3 weeks; for those patients without amputation, 6 weeks are recommended.
For DFI involving skin and soft tissue, treatment duration is typically 1–2 weeks (up to 4 weeks if improvement is slow); empiric treatment should focus on gram-positive bacteria, including Staphylococcus aureus.
Avoid antibiotics in the absence of signs or symptoms of infection in diabetic foot ulcers.
Perform MRI if plain x-rays and probe-to-bone testing are inconclusive for suspected osteomyelitis.
You are correct. Use of adjunctive therapies (e.g., G-CSF, topical antiseptics, silver, honey, bacteriophages, topical antibiotics, hyperbaric oxygen) are NOT recommended to promote healing according to the latest evidence-based guideline recommendations for Diagnosis and Management of Diabetes-Related Foot Infections from the International Working Group on the Diabetic Foot/Infectious Diseases Society of America (IWGDF/IDSA).

The present guideline is an update of the 2019 IWGDF guideline on the diagnosis and management of foot infections in persons with diabetes mellitus.


Source: Senneville E, et al. (2023, October 2). Clin Infect Dis. IWGDF/IDSA Guidelines on the Diagnosis and Treatment of Diabetes-related Foot Infections (IWGDF/IDSA 2023). PubMed(R) abstract
By rray, 8 November, 2023